Rep. Emily Randall

Maddy summaryHR 6391, the Save Oak Flat from Foreign Mining Act, repeals Section 3003 of the 2014 National Defense Authorization Act that would have transferred Oak Flat (2,422 acres in Arizona’s Tonto National Forest) to Resolution Copper for mining. The bill withdraws Oak Flat from all public land use, preventing the foreign-owned mining venture (Rio Tinto/BHP) from extracting copper beneath the site for export to China. It directly protects the area, which is a sacred site for Indigenous peoples and a National Register Historic Property, from a mine projected to consume 250 billion gallons of groundwater over 40 years and cause significant land subsidence. The bill halts a process that would have allowed foreign corporations to mine copper from public land without requiring domestic smelting or benefiting U.S. consumers.

Maddy summaryHRES 920 is a ceremonial resolution celebrating the 50th anniversary of the Individuals with Disabilities Education Act (IDEA) on November 29, 2025. It recognizes IDEA’s historical impact - establishing the right to free, appropriate public education in the least restrictive environment for children with disabilities - and notes how it transformed access to education after over 1 million children were previously excluded from schools. The resolution does not create new policy or funding; it solely commemorates IDEA’s legacy, honors the students and families it has served, and acknowledges educators and advocates who advanced its implementation. This is a symbolic gesture with no direct effect on current law or services.

Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.  Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.  The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)

Maddy summaryHR 6318, the No GOUGE Act, prohibits large businesses from excessively raising prices on goods affected by tariffs or planned tariffs (e.g., imports subject to new tariffs) for five years after the tariff takes effect. It specifically targets companies with over $100 million in U.S. revenue, banning price hikes that exceed the actual cost of the tariff plus legitimate operational expenses (excluding executive pay or stock buybacks). The Federal Trade Commission (FTC) enforces this by presuming violations if large firms (over $1 billion revenue) raise prices beyond pre-tariff averages during "tariff shock" periods, though companies can rebut this by proving costs were genuinely tied to the tariff. The law aims to prevent price gouging by ensuring tariff costs - not profit motives - drive price changes for consumers.

Maddy summaryHRES 909 is a House resolution affirming that immigrant justice and reproductive justice are interconnected and must be addressed together. It calls on the Department of Homeland Security to reinstate protections for pregnant individuals in detention, eliminate the 5-year bar restricting immigrants’ access to federal health programs like Medicaid, and implement transparent oversight of reproductive health care in detention facilities. The resolution also urges Congress to remove barriers to health care access for immigrants and requires federal agencies to report on policies affecting reproductive health care for detained individuals. This resolution directly affects policies toward immigrants in detention, particularly regarding access to abortion, prenatal care, and mental health services, but does not create new laws.

Maddy summaryHRES 899 is a symbolic House resolution recognizing the Transgender Day of Remembrance and memorializing transgender people killed by violence in 2024-2025. It directly affects transgender individuals, particularly transgender women of color, by acknowledging the epidemic of violence against them - citing 27 U.S. victims (including names like Rick Alastor Newman and Kyla Jane Walker) and 241 global cases in 2025. The resolution’s key provisions include formally recognizing the violence epidemic, memorializing specific lives lost, and affirming the need for solutions to protect transgender people. It does not create new laws but expresses congressional support for addressing systemic violence and discrimination faced by transgender communities.

Maddy summaryHR 6215, the Small Business RELIEF Act, exempts small businesses from import duties imposed under Executive Order 14257 (90 Fed. Reg. 15041) for goods they import or use. It requires the President to refund duties paid by small businesses within 90 days of the bill's enactment. The bill defines "small business concern" using the standard Small Business Act criteria (15 U.S.C. 632). This directly affects small businesses importing goods, providing immediate cost relief by removing a specific tariff and refunding past payments.

Maddy summaryThe Revitalize Our Neighborhoods Act of 2025 creates a competitive grant program administered by the Department of Housing and Urban Development (HUD) to eliminate blight and revitalize neighborhoods. It provides funding specifically for states, local governments, or multi-jurisdictional entities to carry out activities like demolishing deteriorated structures, boarding vacant properties, renovating abandoned buildings, and constructing affordable housing - all limited to low-income communities. Recipients must contribute at least 15% in matching funds (from federal programs, local sources, or property sales) and submit detailed 5-year plans for how the funds will be used. The bill prohibits using funds to acquire occupied homes and requires annual reports on project outcomes, geographic distribution, and populations assisted.

Maddy summaryHR 6206, the Protect Culturally Sensitive Information Act, protects specific information shared by Indian Tribes, Alaska Native Entities, and Native Hawaiian Organizations with the federal government. It prohibits public disclosure of designated "culturally sensitive information," such as locations of sacred sites, burial sites, cultural items, or religious practices, unless tribes consent in writing or under strict court-ordered circumstances with mitigation steps. Federal agencies must consult with tribal representatives on handling such information and store it securely, with limited exceptions for lawful court orders requiring agencies to notify tribes and seek redaction or sealed review. The bill directly affects tribal governments and their representatives by giving them authority to designate sensitive information and control its disclosure.

Maddy summaryThis bill expands Medicare's drug price negotiation program to cover 50 drugs (up from 20) and requires health insurers to apply negotiated prices to cost-sharing for beneficiaries. It establishes annual out-of-pocket cost-sharing limits for prescription drugs under group health plans and insurance coverage, with specific limits of $2,000 for self-only coverage in 2027 that will increase annually. The bill also sets specific cost-sharing limits for insulin products, requiring coverage with no deductible and cost-sharing of no more than $35 per 30-day supply or 25% of the negotiated price. These provisions affect Medicare beneficiaries, people with group health plans, and health insurers across the country. The bill applies to plan years beginning on or after January 1, 2027.